Genetic characterization of T-PLL reveals two major biologic subgroups andJAK3mutations as prognostic marker
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Genetic characterization of T-PLL reveals two major biologic subgroups andJAK3mutations as prognostic marker
Authors
Keywords
-
Journal
GENES CHROMOSOMES & CANCER
Volume 55, Issue 1, Pages 82-94
Publisher
Wiley
Online
2015-10-24
DOI
10.1002/gcc.22313
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Recurrent CDKN1B (p27) mutations in hairy cell leukemia
- (2015) S. Dietrich et al. BLOOD
- TP53 mutations occur in 15.7% of ALL and are associated with MYC-rearrangement, low hypodiploidy, and a poor prognosis
- (2014) A. Stengel et al. BLOOD
- Integrated genomic sequencing reveals mutational landscape of T-cell prolymphocytic leukemia
- (2014) M. J. Kiel et al. BLOOD
- Haploinsufficiency of ETV6 and CDKN1B in patients with acute myeloid leukemia and complex karyotype
- (2014) Simone Feurstein et al. BMC GENOMICS
- Allogeneic hematopoietic stem cell transplantation for T-prolymphocytic leukemia: a report from the French society for stem cell transplantation (SFGM-TC)
- (2014) Thierry Guillaume et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Recurrent mutation ofJAK3in T-cell prolymphocytic leukemia
- (2014) Anke K. Bergmann et al. GENES CHROMOSOMES & CANCER
- BCOR and BCORL1 mutations in myelodysplastic syndromes and related disorders
- (2013) F. Damm et al. BLOOD
- Sequential chemoimmunotherapy of fludarabine, mitoxantrone, and cyclophosphamide induction followed by alemtuzumab consolidation is effective in T-cell prolymphocytic leukemia
- (2013) Georg Hopfinger et al. CANCER
- How I treat prolymphocytic leukemia
- (2012) C. Dearden BLOOD
- Biallelic ATM Inactivation Significantly Reduces Survival in Patients Treated on the United Kingdom Leukemia Research Fund Chronic Lymphocytic Leukemia 4 Trial
- (2012) Anna Skowronska et al. JOURNAL OF CLINICAL ONCOLOGY
- Alemtuzumab therapy in T-cell prolymphocytic leukemia: comparing efficacy in a series treated intravenously and a study piloting the subcutaneous route
- (2011) C. E. Dearden et al. BLOOD
- Whole-exome sequencing identifies somatic mutations of BCOR in acute myeloid leukemia with normal karyotype
- (2011) V. Grossmann et al. BLOOD
- Gene expression of BAALC, CDKN1B, ERG, and MN1 adds independent prognostic information to cytogenetics and molecular mutations in adult acute myeloid leukemia
- (2011) Claudia Haferlach et al. GENES CHROMOSOMES & CANCER
- ATM and chronic lymphocytic leukemia: mutations, and not only deletions, matter
- (2011) D. Rossi et al. HAEMATOLOGICA
- ATM gene alterations in chronic lymphocytic leukemia patients induce a distinct gene expression profile and predict disease progression
- (2011) A. Guarini et al. HAEMATOLOGICA
- Stem cell transplantation after alemtuzumab in T-cell prolymphocytic leukaemia results in longer survival than after alemtuzumab alone: a multicentre retrospective study
- (2010) Biju Krishnan et al. BRITISH JOURNAL OF HAEMATOLOGY
- TP53Mutation and Survival in Chronic Lymphocytic Leukemia
- (2010) Thorsten Zenz et al. JOURNAL OF CLINICAL ONCOLOGY
- Molecular allelokaryotyping of T-cell prolymphocytic leukemia cells with high density single nucleotide polymorphism arrays identifies novel common genomic lesions and acquired uniparental disomy
- (2009) D. Nowak et al. HAEMATOLOGICA
- Prolymphocytic leukaemia of B- and T-cell subtype: a state-of-the-art paper
- (2008) M. Dungarwalla et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Mutations of the TP53 gene in acute myeloid leukemia are strongly associated with a complex aberrant karyotype
- (2008) C Haferlach et al. LEUKEMIA
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started